GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » ROE %

NeoGenomics (NeoGenomics) ROE % : -11.61% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NeoGenomics's annualized net income for the quarter that ended in Mar. 2024 was $-108.2 Mil. NeoGenomics's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $932.5 Mil. Therefore, NeoGenomics's annualized ROE % for the quarter that ended in Mar. 2024 was -11.61%.

The historical rank and industry rank for NeoGenomics's ROE % or its related term are showing as below:

NEO' s ROE % Range Over the Past 10 Years
Min: -13.7   Med: -0.57   Max: 2.76
Current: -8.88

During the past 13 years, NeoGenomics's highest ROE % was 2.76%. The lowest was -13.70%. And the median was -0.57%.

NEO's ROE % is ranked worse than
52.78% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.58 vs NEO: -8.88

NeoGenomics ROE % Historical Data

The historical data trend for NeoGenomics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics ROE % Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 0.69 -0.93 -13.70 -9.07

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.49 -10.08 -7.78 -6.07 -11.61

Competitive Comparison of NeoGenomics's ROE %

For the Diagnostics & Research subindustry, NeoGenomics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's ROE % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's ROE % distribution charts can be found below:

* The bar in red indicates where NeoGenomics's ROE % falls into.



NeoGenomics ROE % Calculation

NeoGenomics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-87.968/( (998.023+941.537)/ 2 )
=-87.968/969.78
=-9.07 %

NeoGenomics's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-108.244/( (941.537+923.41)/ 2 )
=-108.244/932.4735
=-11.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


NeoGenomics  (NAS:NEO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-108.244/932.4735
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-108.244 / 624.96)*(624.96 / 1660.784)*(1660.784 / 932.4735)
=Net Margin %*Asset Turnover*Equity Multiplier
=-17.32 %*0.3763*1.7811
=ROA %*Equity Multiplier
=-6.52 %*1.7811
=-11.61 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-108.244/932.4735
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-108.244 / -110.724) * (-110.724 / -112.676) * (-112.676 / 624.96) * (624.96 / 1660.784) * (1660.784 / 932.4735)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9776 * 0.9827 * -18.03 % * 0.3763 * 1.7811
=-11.61 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NeoGenomics ROE % Related Terms

Thank you for viewing the detailed overview of NeoGenomics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913

NeoGenomics (NeoGenomics) Headlines

From GuruFocus